Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PET tracer · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PET tracer (BAY94-9392) | DRUG | A radioactive dose of 300 MBq of the study drug with a total quantity of \</= 0.1 mg will be administered as slow intravenous bolus injection over up to 60 seconds |
Inclusion Criteria: * Males/females \>/= 18 years * Patients with a diagnosis of primary prostate cancer (biopsy proven) and scheduled for radical prostatectomy or patients with prostate tumor recurrence (Patients with advanced tumor disease and a high likelihood to display lymph node metastasis ar...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
The PET tracer is an investigational small molecule being studied for use in oncology, specifically for imaging neoplasms, or tumors. It is being developed as a diagnostic imaging agent to explore tumor accumulation in patients with cancer. The drug is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
The PET tracer is a small molecule designed for positron emission tomography imaging in oncology. While its specific molecular target is not disclosed, it is intended to accumulate in tumors, allowing visualization of neoplasms. This mechanism enables detection and characterization of cancerous lesions in patients undergoing imaging procedures.
The PET tracer is being developed by Lantheus Holdings, Inc., a company traded on the NASDAQ under the ticker symbol LNTH. Lantheus is responsible for the clinical development of this investigational imaging agent, which is currently in Phase 1 trials for use in patients with neoplasms.
The PET tracer is in Phase 1 clinical development. It has completed one Phase 1 trial, which was an uncontrolled, non-randomized study that enrolled 30 participants. The drug remains investigational and has not received FDA approval, as it is still in the early stages of clinical evaluation for oncology imaging.
The PET tracer has been studied in one clinical trial, identified as NCT01186601, titled "Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer." This Phase 1 study was completed in the United States and enrolled 30 adult participants with neoplasms. The trial was uncontrolled and did not use randomization or blinding.
Yes, the PET tracer is also known as BAY94-9392, as indicated by the clinical trial title for study NCT01186601. This alternative name was used in the Phase 1 trial that explored tumor accumulation of the agent in patients with cancer. Both names refer to the same investigational imaging compound.